Targeting covid inflammation in lungs may yield better results than targeting whole body

These findings provide evidence for why targeting inflammation outside the lungs [against covid] has been disappointing so far. Instead, a more targeted approach that inhibits the expression and activation of complement proteins in lung cells could yield better results. For example, the researchers found that pairing Remdesivir with Ruxolitinib inhibited the complement response much more effectively than a monotherapy of the drugs independently, using an in vitro model of alveolar cells.

The “Unexpected” Reason Why COVID Antivirals Don’t Work

This may be why inhalers containing budesonide greatly lower covid symptoms: Over-the-counter asthma inhalers show 90% reduction of covid symptoms.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s